Astellas Gears Up To Launch Caduet With Pfizer; Ramps Up Oncology Franchise With Seattle Genetics Agreement
This article was originally published in PharmAsia News
Executive Summary
Pfizer Japan and Tokyo-based Astellas announced Nov. 26 that that they will launch combo drug Caduet (amlodipine/atorvastatin) in Japan Dec. 2
You may also be interested in...
Astellas Signs Strategic Oncology Partnership With Ambit After Medivation Success
Just days after Takeda signed a strategic alliance with Seattle Genetics for oncology antibody drug development, Astellas announced Dec. 18 a worldwide agreement with San Diego-based Ambit Bioscience to jointly develop and commercialize FMS-like tyrosine kinase-3 inhibitors for multiple oncology and non-oncology indications
Astellas Signs Strategic Oncology Partnership With Ambit After Medivation Success
Just days after Takeda signed a strategic alliance with Seattle Genetics for oncology antibody drug development, Astellas announced Dec. 18 a worldwide agreement with San Diego-based Ambit Bioscience to jointly develop and commercialize FMS-like tyrosine kinase-3 inhibitors for multiple oncology and non-oncology indications
Astellas Signs Strategic Oncology Partnership With Ambit After Medivation Success
The deal is the third oncology partnership agreement signed by Astellas with a U.S. biotech in as many months..